(Q40585149)

21 September 2017

0 references

Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis (English)

1 reference

21 September 2017

Paolo Furno

1

1 reference

PubMed ID

11937423

21 September 2017

Giampaolo Bucaneve

series ordinal

2

1 reference

PubMed ID

11937423

21 September 2017

Albano Del Favero

series ordinal

3

1 reference

21 September 2017

1 April 2002

1 reference

Lancet Infectious Diseases

21 September 2017

1 reference

21 September 2017

2

1 reference

21 September 2017

4

1 reference

21 September 2017

231-242

1 reference

Significance of antimicrobial synergism for the outcome of gram negative sepsis

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Synergistic combinations of antibiotics in gram-negative bacillary infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

A method for assessing the quality of a randomized control trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Quality assessment of randomized controlled trials of contrast media

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

A comparison of statistical methods for combining event rates from clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Ceftazidime as first-line therapy for fever in acute leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Ceftazidime with or without vancomycin vs. cephalothin, carbenicillin and gentamicin as the initial therapy of the febrile neutropenic pediatric cancer patient.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Imipenem/cilastatin versus piperacillin plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with haematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Comparison of imipenem versus cefuroxime plus tobramycin as empirical therapy for febrile granulocytopenic patients and efficacy of vancomycin and aztreonam in case of failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Re

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: a randomized, single-center phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Ceftazidime as a single agent in the management of children with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

A randomised trial of empirical antibiotic therapy in febrile neutropenic patients with hematological disorders: ceftazidime versus azlocillin plus amikacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Ceftriaxone vs. azlocillin and netilmicin in the treatment of febrile neutropenic children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Ceftazidime monotherapy is as effective as ceftazidime combined with gentamicin in the treatment of febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of C

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Ceftazidime versus ceftazidime plus tobramycin in febrile neutropenic children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

The impact of stopping rules on heterogeneity of results in overviews of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Ceftazidime Monotherapy for Empiric Treatment of Febrile Neutropenic Patients: A Metaanalysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900241-4

7 January 2021

10.1016/S1473-3099(02)00241-4

Identifiers

DOI

1 reference

21 September 2017

1 reference

PubMed ID

11937423